Hero Finding
74% of laboratory decision-makers would likely adopt a rapid automated ESR platform, and the automation gap explains why.
CRP testing is largely a solved problem: 40% of laboratories run it fully automated. ESR lags at every automation band, with 15% fully automated, 53% at half-automated or worse, and 9% still running a completely manual process. The demand signal matches the gap, and the ordering physicians independently validated the case for a faster, integrated solution.
% of laboratory decision-makers · n=53 · adoption intent, rated concept benefit, and current automation share · values as reported
Key Findings
What the research surfaced for the entry decision.
Six signals separated the modernized half of the category from the lagging half, each read across institution type and region on both stakeholder tracks.
CRP is effectively modernized. ESR lags at every automation band.
58% of laboratories run CRP at 76% automation or higher and 40% run it fully automated. Only 32% reach that automation level for ESR, 15% run it fully automated, and 53% run ESR at half-automated or worse, including 9% still on a completely manual process. The category looks mature in aggregate. Its ESR half does not, which means the entry product competes against workflow pain rather than against a satisfied incumbent.
ESR turnaround runs an hour or longer in 64% of laboratories.
Turnaround follows the automation pattern. 64% of laboratories report ESR results taking an hour or longer, and 26% take more than two hours. Framed specifically on minutes-versus-hours turnaround, 74% of laboratory decision-makers would definitely or probably adopt, and the qualitative track tied the value to emergency and acute-care settings where disposition decisions wait on the result.
Laboratories named the gap unprompted: insufficient automation leads the pain list at 43%.
Asked for their most significant pain points in inflammation marker testing, laboratory decision-makers put insufficient automation first at 43%, with turnaround too long for clinical needs and high cost per test tied at 36%, and LIS integration difficulty at 32%. When the study put the implied product in front of them, the response matched the complaint.
Adoption intent is broad and mostly soft: 74% likely, 26% very likely.
74% of laboratory decision-makers, 39 of 53, said they would be very or somewhat likely to adopt a rapid automated ESR system, against only 8% unlikely. An integrated analyzer running both CRP and ESR on one instrument was rated extremely or very beneficial by 68%. The intent splits 26% very likely against 47% somewhat likely, so conversion depends on the commercial motion into each account rather than on the concept itself.
Physicians already consume the two markers as a pair.
Every physician in the sample orders both markers at least occasionally. 61% order CRP and ESR together in at least 60% of their cases, and 35% co-order in more than 90% of cases. Faster turnaround would change actual patient management for most of them: 58% called minutes-versus-hours results extremely or very meaningful, and none dismissed it. An integrated instrument maps onto how the tests are actually consumed rather than requiring physicians to change anything.
Platform purchases clear four functions, and laboratory leadership orchestrates the process.
The purchasing-journey map codes who controls a platform decision: laboratory leadership orchestrates the process in 74% of accounts, procurement manages the vendor interface in 70%, finance gatekeeps in 62%, and IT or biomedical engineering validates integration in 21%. Most laboratories call an existing vendor relationship very important, which sets the bar a new entrant clears on service, evidence, and cost per test.
The laboratories forecast a drift toward specific markers. The physicians who order the tests do not expect replacement.
Going in, the central strategic risk was category obsolescence: 79% of laboratory decision-makers expect the clinical balance to shift toward newer specific inflammation markers over the next 5 to 10 years, and 57% expect CRP to gain share within the pair while ESR usage declines. The physician track tempered that drift. Only 19% of physicians expect specific markers to fully replace the generic pair even on a 10-year horizon, and 91% of laboratory decision-makers still rate the category stable or growing. Together those results frame the entry as a real but windowed opportunity in a workflow-modernization market rather than a growth market.
All labs face staffing shortages and automation is key to future work flow.
Laboratory Director · Community Hospital Laboratory · North America
Study Design
N=84laboratory decision-makers and ordering physicians
Three regions, 15 quota cells
AI-moderated quant + qual interviews with auto-looped vendor batteries
Two screened tracks ran inside one instrument. Laboratory directors and managers spoke to platforms, workflows, purchasing, and switching triggers; ordering physicians spoke to clinical utilization, co-ordering behavior, and what faster results would change at the bedside. Quotas held 15 regional cells across institution type and physician category, fielded in a single 9-day window through two independent expert networks, with no interview under 19 minutes. Per-vendor satisfaction batteries were auto-looped from each laboratory's own platform roster, and every finding was significance-tested across institution type crossed with region.
Sample by segment
Mix
What the guide covered
- Current CRP and ESR workflows, automation levels, and turnaround times
- Per-vendor platform satisfaction, 10 attributes per platform, auto-looped across each laboratory's installed base
- Pain points and evaluation triggers in inflammation marker testing
- The purchasing journey: who initiates, evaluates, approves, and blocks a platform purchase
- Concept reaction: a rapid automated ESR method and an integrated CRP plus ESR analyzer
- Physician ordering patterns, co-ordering behavior, and turnaround impact on care decisions
- Market outlook: category viability and the generic-to-specific marker shift over 5 to 10 years
Who qualified
- Laboratories run both markers in-house and sign off results
- Physicians order both markers regularly and hold test-selection influence
- Decision-involvement and volume-awareness screener terminations on both tracks
- Recruited through two independent expert networks · no interview under 19 minutes
Crosstab · Automation by Marker
Workflow automation distribution, CRP versus ESR.
Share of laboratories at each automation band for the two markers that share the category, n=53. Stat-tested crosstabulation across institution type and region confirmed the gap as structural rather than local. Highlighted row = the lagging marker, where the entry opportunity concentrates.
| Fully automated | 76-99% | 51-75% | 26-50% | 1-25% | Completely manual | |
|---|---|---|---|---|---|---|
| CRP workflow | 40% | 19% | 17% | 13% | 9% | 2% |
| ESR workflow | 15% | 17% | 15% | 25% | 19% | 9% |
n=53 laboratories · 58% run CRP at 76% automation or above · only 32% for ESR · 53% run ESR half-automated or worse · The automation gap holds across region and institution type
Voice of Customer
What laboratory leaders and physicians actually said.
Verbatim excerpts from the AI-moderated interviews, selected to span both stakeholder tracks and all three regions: the automation gap, integration demand, co-ordering behavior, and category outlook.
“Sometimes I need to see the inflammatory marker before I make a decision on the course of action. If there was a way to get a result instantly at the point of care, I could tell the patient the plan before they even left the clinic.”
“There's no automation to it. So that's the greatest limitation. It has a greater turnaround time.”
“I think it will be very appealing if there is an all-in-one automatic analyzer for both CRP and ESR in our laboratory.”
“So the main rationale is that I want to see the agreement between the two tests, and I want to see the extent of abnormal tests if both are abnormal.”
“I think its use has been stable over the years because there has been very limited innovation in this space.”
“Inflammatory markers are very reliable to distinguish between acute infections and chronic inflammations. If this turnaround time becomes fast, we can change and provide the best type of treatment to our patients, so that the cost is less and the effectiveness is much higher.”
Implications · what the evidence supports
Three readings from the research.
What the strategy team carried into the entry decision, grounded in the two-track data.
The entry opportunity concentrates in the unautomated half of the pair.
CRP is largely solved: 58% of laboratories run it at 76% automation or above. ESR lags at every band, and the demand signal matches the gap, with 74% likely to adopt a rapid automated ESR platform and 68% rating an integrated CRP plus ESR analyzer extremely or very beneficial. The product attributes that collect the demand are automation, speed, integration, and cost per test.
Conversion runs through a multi-stakeholder purchasing journey inside the account.
Adoption intent is broad but mostly soft, 26% very likely against 47% somewhat likely. Laboratory leadership orchestrates selection in 74% of accounts, procurement manages the vendor interface in 70%, finance gatekeeps in 62%, and IT or biomedical engineering validates integration in 21%. Most laboratories call an existing vendor relationship very important, so the commercial motion into each account determines how much of the 74% converts.
The category reads as durable but windowed.
91% of laboratory decision-makers rate generic inflammation testing stable or growing, 43% growing and 47% stable, while 79% expect a long-run shift toward specific markers. Physicians temper the drift, with only 19% expecting full replacement even at 10 years. The entry case the data supports is a workflow-modernization market with the economics anchored to modernizing the installed base rather than riding category growth.
Signals the data flagged
- 74% adoption intent for a rapid automated ESR platform, 8% opposed
- 68% rate an integrated CRP plus ESR analyzer extremely or very beneficial
- 61% of physicians co-order both markers in at least 60% of cases, none never co-order
- 91% of laboratory decision-makers rate the category stable or growing
Risks the data surfaced
| Long-run shift toward specific inflammation markers | Med |
| Soft adoption intent converts below the 74% headline | Med |
| Incumbent vendor relationships slow platform displacement | High |
| ESR usage declines within the pair as CRP gains share | Med |